• 1. An atom-economical protocol for direct conversion of Baylis–Hillman alcohols to β-chloro aldehydes in water?
  Raktani Bikshapathi,Sai Prathima Parvathaneni,Vaidya Jayathirtha Rao Green Chem., 2017,19, 4446-4450
• 2. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 3. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 4. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 5. Alumina coating on 5 V lithium cobalt fluorophosphate cathode material for lithium secondary batteries – synthesis and electrochemical properties?
  S. Amaresh,K. Karthikeyan,K. J. Kim,Y. S. Lee RSC Adv., 2014,4, 23107-23115

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Aniline and substituted anilines

Research Brief on 3-Bromo-2-chloro-5-fluoroaniline (CAS: 187929-81-3) in Chemical and Biomedical Applications

3-Bromo-2-chloro-5-fluoroaniline (CAS: 187929-81-3) is a halogenated aniline derivative that has garnered significant attention in recent years due to its versatile applications in pharmaceutical and agrochemical synthesis. This compound serves as a key intermediate in the development of active pharmaceutical ingredients (APIs) and specialty chemicals. Recent studies have highlighted its role in the synthesis of novel heterocyclic compounds with potential therapeutic properties, particularly in oncology and antimicrobial research.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 3-Bromo-2-chloro-5-fluoroaniline as a precursor in the synthesis of kinase inhibitors targeting EGFR and VEGFR pathways. The researchers employed palladium-catalyzed cross-coupling reactions to incorporate this building block into more complex molecular architectures, yielding compounds with promising in vitro activity against non-small cell lung cancer cell lines. The study reported IC50 values in the low micromolar range for several derivatives, suggesting potential for further optimization.

In the field of material science, 3-Bromo-2-chloro-5-fluoroaniline has been investigated as a monomer for the synthesis of conductive polymers. A recent patent application (WO2023056789) describes its use in creating fluorinated polyaniline derivatives with enhanced thermal stability and electrical conductivity. These materials show potential for applications in biosensors and organic electronics, particularly in environments requiring chemical resistance.

The compound's safety profile has been the subject of recent toxicological assessments. A 2024 regulatory study submitted to the European Chemicals Agency (ECHA) evaluated its acute and chronic toxicity endpoints, concluding that while it demonstrates moderate acute oral toxicity (LD50 = 320 mg/kg in rats), proper handling procedures can mitigate occupational risks. The study emphasized the importance of appropriate personal protective equipment when working with this compound in laboratory settings.

From a synthetic chemistry perspective, novel methodologies for the preparation of 3-Bromo-2-chloro-5-fluoroaniline have emerged. A recent Organic Process Research & Development publication (2023) described a continuous flow chemistry approach that improves yield (85% vs. traditional batch's 68%) while reducing hazardous waste generation. This advancement aligns with the pharmaceutical industry's growing emphasis on green chemistry principles and process intensification.

Market analysis indicates growing demand for 3-Bromo-2-chloro-5-fluoroaniline, with projected compound annual growth rate (CAGR) of 6.2% from 2023 to 2030 according to a recent industry report. This growth is primarily driven by increasing R&D investment in fluorinated pharmaceuticals and the expansion of contract manufacturing organizations specializing in halogenated intermediates.

Future research directions appear to focus on expanding the compound's utility in PROTAC (Proteolysis Targeting Chimera) development and as a building block for fluorine-18 labeled PET tracers. Preliminary results from ongoing studies suggest that the unique halogen pattern of 3-Bromo-2-chloro-5-fluoroaniline may enable novel approaches to targeted protein degradation and molecular imaging.

• 1702023-23-1(3-Bromo-2-chloro-6-fluoroaniline, tech)
• 112062-64-3(BENZENAMINE, 3-BROMO-2-CHLORO-4,5-DIFLUORO-)
• 885453-49-6(4-bromo-2-chloro-6-fluoroaniline)
• 1616244-35-9(2-Chloro-3-bromo-5,6-difluoroaniline)
• 115843-99-7(4-Bromo-3-chloro-2-fluoroaniline)
• 116369-24-5(4-Bromo-5-chloro-2-fluoroaniline)
• 1955530-58-1(5-Bromo-2-chloro-4-fluoroaniline hydrochloride)
• 305795-89-5(5-Bromo-2-chloro-4-fluoroaniline)
• 111010-07-2(5-bromo-4-chloro-2-fluoroaniline)
• 1000572-63-3(4-Bromo-2-chloro-5-fluoroaniline)